ANX-530 causes fewer injection site reactions than Navelbine in trial

San Diego, USA-based Adventrx Pharmaceuticals, an R&D focused biopharmaceutical firm, says that ANX-530 (vinorelbine emulsion), its lung cancer treatment, has demonstrated a statistically-significant reduction in injection site reactions in a trial comparing it with bioMerieux-Pierre Fabre's Navelbine (vinorelbine). The finding follows on from data released in November last year, which showed that the drug was equivalent to Navelbine in terms of its pharmacokinetics.

Adventrx' chief executive, Evan Levine, welcomed the news, commenting: "we are extremely encouraged by these data, and pleased that our goal to improve the safety of vinorelbine was observed in the clinic." He added that it was particularly gratifying that, even in the relatively small scale study, which enrolled just 31 patients, statistical differences in injection site reactions had been observed. Adventrx plans to submit a New Drug Application to the Food and Drug Administration later this year.